K. Haslett

发表

Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone

C. Faivre-Finn, F. Blackhall, A. Jackson, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

RadBone: bone toxicity following pelvic radiotherapy – a prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy

R. Bristow, A. Whetton, M. Eden, 2022, BMJ Open.

Post-treatment lymphocytopaenia, integral body dose and overall survival in lung cancer patients treated with radical radiotherapy.

M. V. van Herk, C. Faivre-Finn, A. McWilliam, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer – a retrospective analysis of toxicity and outcomes

D. Grose, C. Paterson, A. James, 2014, Scottish medical journal.

Sequential chemotherapy-radiotherapy as adjuvant treatment of high-risk endometrial carcinoma: a retrospective review of the Manchester experience

G. Jayson, E. Crosbie, A. Clamp, 2021 .

Palliative radiotherapy in cancers of female genital tract: Outcomes and prognostic factors.

P. Hoskin, A. Choudhury, A. Cree, 2022, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial.

E. Smit, C. Faivre-Finn, S. Senan, 2017, Lung cancer.

Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging

C. Faivre-Finn, C. Dive, F. Blackhall, 2017, Clinical lung cancer.

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

W. Ryder, C. Faivre-Finn, F. Blackhall, 2021, Clinical and translational radiation oncology.

Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study

W. Ryder, C. Faivre-Finn, S. Harden, 2020, International journal of radiation oncology, biology, physics.

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study

C. Faivre-Finn, S. Harden, G. Hanna, 2016, BMJ Open.

Hyperfractionated and accelerated radiotherapy in non-small cell lung cancer.

C. Faivre-Finn, M. Stuschke, C. Pöttgen, 2014, Journal of thoracic disease.

Electronic Patient Reported Outcomes significantly improved toxicity data collection and were acceptable to both patients and clinicians in lung cancer radiotherapy outpatient clinics.

J. Kennedy, L. Lee, N. Bayman, 2017 .

Short Communication: Management of patients with extensive-stage small-cell lung cancer treated with radiotherapy: A survey of practice

D. de Ruysscher, R. Dziadziuszko, C. Faivre-Finn, 2018, Cancer treatment and research communications.

Abstract P5-10-25: Docetaxel/Cyclophosphamide (TC) Chemotherapy for Early Breast Cancer: Is Primary g-csf Prophylaxis Necessary?

I. Macpherson, G. Lumsden, K. Haslett, 2010 .

Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy: A secondary analysis of the Phase III CREST trial.

E. Smit, C. Faivre-Finn, S. Senan, 2017, Lung cancer.